熊去氧胆酸(Ursodiol) - 药物靶点：FXR_在研适应症：胆汁反流性胃炎，胆汁淤积性肝病，慢性丙型肝炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid、(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid、3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid

+ [25]

靶点

FXR

作用方式

拮抗剂

作用机制

FXR拮抗剂(胆汁酸受体FXR拮抗剂)

治疗领域

感染消化系统疾病内分泌与代谢疾病+ [1]

在研适应症

胆汁反流性胃炎胆汁淤积性肝病慢性丙型肝炎+ [8]

非在研适应症

腺瘤性结肠息肉病慢性心力衰竭纤维化+ [1]

原研机构

Mitsubishi Tanabe Pharma Factory Ltd.

在研机构

深圳市康哲生物科技有限公司

宜昌人福药业有限责任公司Teva Branded Pharmaceutical Products R&D, Inc.

+ [8]

非在研机构

Axcan Pharma (Australia) Pty Ltd.

权益机构

Aptalis Pharma LLCForest Laboratories, Inc.

最高研发阶段批准上市

首次获批日期

日本 (1961-11-27),

消化不良

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C24H40O4

InChIKeyRUDATBOHQWOJDD-UZVSRGJWSA-N

CAS号128-13-2

关联

283

项与熊去氧胆酸相关的临床试验

NCT06922669

/ Not yet recruitingN/AIIT

Efficacy and Safety of Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia: A Multicenter Randomized Controlled Trial

Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially patients with hyperbilirubinemia. However, the available evidence remains controversial and its quality is also very limited. Herein, a multicenter randomized controlled trial (RCT) has been designed to explore the efficacy and safety of glucocorticoids in patients with acute DILI and hyperbilirubinemia.

开始日期2025-06-01

申办/合作机构

中国人民解放军北部战区总医院

NCT06884748

/ Not yet recruiting早期临床1期IIT

PREVENTION of RECURRENCE of CLOSTRIDIOIDES DIFFICILE COLITIS with URSODEOXYCHOLIC ACID (UCDA) AS a SUPPLEMENT to STANDARD THERAPY

The goal of this clinical trial is to determine whether Ursodeoxycholic Acid (UDCA) can help prevent recurrence of Clostridioides difficile (C. diff) colitis when used along with standard antibiotic treatment. C. diff colitis is a serious infection that can return after treatment, and researchers want to see if UDCA can reduce this risk.
This study aims to answer three main questions. First, can UDCA help prevent C. diff from returning after standard treatment? Second, does adding UDCA to treatment lower the need for repeated antibiotic use? Third, is UDCA safe and well-tolerated for people with C. diff?
Participants in the study will be adults diagnosed with C. diff colitis who have risk factors for recurrence. Each participant will receive standard antibiotic treatment, which may include Vancomycin, Fidaxomicin, or Metronidazole. In addition to their antibiotic therapy, participants will take UDCA at a dose of 500 mg three times a day for up to eight weeks. If a participant's stool test shows they are C. diff negative at four weeks, they will stop taking UDCA early.
Researchers will monitor participants throughout the study. Stool samples will be tested at the beginning, after four weeks, and at the end of the study. If a participant develops diarrhea, a stool test will check for C. diff. If C. diff is negative, the UDCA dose will be reduced. Weekly phone calls will be made to check for side effects and ensure participants are following the treatment plan.
C. diff colitis is a common and serious infection, with up to 46 percent of high-risk patients experiencing recurrence. Current treatments rely on antibiotics, which can disrupt gut bacteria and increase the risk of reinfection. UDCA is a naturally occurring bile acid that may help prevent C. diff from growing, reducing the need for repeated antibiotic treatment. If successful, this study could introduce a new way to prevent C. diff from coming back, helping patients recover more effectively while reducing antibiotic use.
Eligible participants must be at least 18 years old, have a positive C. diff test, and be receiving standard antibiotic treatment for C. diff. People who have severe or life-threatening C. diff colitis, a life expectancy of less than six months, serious liver disease, or are pregnant or breastfeeding will not be eligible to participate.
UDCA is FDA-approved and has been used safely for decades in liver diseases and gallstone treatment. Some people may experience mild side effects, such as diarrhea, nausea, or stomach discomfort. Participants will be closely monitored for safety throughout the study.
This trial will take place within the Froedtert and Medical College of Wisconsin healthcare system in Milwaukee, Wisconsin.

开始日期2025-05-01

申办/合作机构

Medical College of Wisconsin

CTRI/2025/04/084464

/ Not yet recruiting临床3期

A randomized, single blind, placebo-controlled, multicentre, Phase III study to evaluate the efficacy and safety of Ursodeoxycholic acid (150/300/450/600 mg) in patients with non-alcoholic fatty liver disease (NAFLD) with transaminitis. - NIL

开始日期2025-04-20

申办/合作机构-

100 项与熊去氧胆酸相关的临床结果

登录后查看更多信息

100 项与熊去氧胆酸相关的转化医学

登录后查看更多信息

100 项与熊去氧胆酸相关的专利（医药）

登录后查看更多信息

10,842

项与熊去氧胆酸相关的文献（医药）

2025-12-31·Future Science OA

Atypical acquired hemophilia linked with primary biliary cholangitis: a unique case presentation

Article

作者: Hachicha, Hend ; Kallel, Faten ; Kallel, Choumous ; Charfi, Maha ; Kallel, Naourez ; Masmoudi, Hatem ; Siala, Nour ; Elloumi, Moez ; Medhaffar, Moez ; Frikha, Imen ; Megdiche, Fatma ; Krichen, Imen

Acquired hemophilia A is an uncommon disease often presented with bleeding episodes causing a significant mortality risk. The main responsible for the threatening hemorrhagic disorder is the Factor VIII autoantibody's development. Acquired inhibitors' presence is frequently idiopathic, but it can be associated with malignancy, pregnancy, drugs and autoimmune diseases. In this report, we present the first case of acquired hemophilia A associated with primary biliary cholangitis. A 48-year-old man, presented with diffuse oral bleeding after a tooth extraction. Hemostasis testing revealed a markedly prolonged activated partial thromboplastin time. The search for an anti-factor VIII inhibitor returned positive. The etiological investigation concluded primary biliary cholangitis, and the patient was treated with bypassing agent, immunosuppressive therapy, and ursodeoxycholic acid.

2025-12-31·Gut Microbes

Raffinose-metabolizing bacteria impair radiation-associated hematopoietic recovery via the bile acid/FXR/NF-κB signaling pathway

Article

作者: Wang, Xin ; Qi, Xiaofei ; Jiao, Yang ; Wang, Jian ; Ren, Jiawei ; Wu, Depei ; Guo, Hongjuan ; Zhou, Zhemin ; Cao, Jianping ; Shen, Jiaqi ; Xie, Shichang ; Yin, Huafang ; Yuan, Nan

Radiation-associated hematopoietic recovery (RAHR) is critical for mitigating lethal complications of acute radiation syndrome (ARS), yet therapeutic strategies remain limited. Through integrated multi-omics analysis of a total body irradiation (TBI) mouse model, we identify Bacteroides acidifaciens-dominated gut microbiota as key mediators of RAHR impairment. 16S ribosomal rRNA sequencing revealed TBI-induced dysbiosis characterized by Bacteroidaceae enrichment, while functional metagenomics identified raffinose metabolism as the most significantly perturbed pathway. Notably, raffinose supplementation (10% w/v) recapitulated radiation-induced microbiota shifts and delayed bone marrow recovery. Fecal microbiota transplantation (FMT) revealed a causative role for raffinose-metabolizing microbiota, particularly Bacteroides acidifaciens, in delaying RAHR progression. Mechanistically, B. acidifaciens-mediated bile acid deconjugation activated FXR, subsequently suppressing NF-κB-dependent hematopoietic recovery. Therapeutic FXR inhibition via ursodeoxycholic acid (UDCA) had been shown to be a viable method for rescuing RAHR. Our results delineated a microbiome-bile acid-FXR axis as a master regulator of post-irradiation hematopoiesis. Targeting B. acidifaciens or its metabolic derivatives could represent a translatable strategy to mitigate radiation-induced hematopoietic injury.

2025-09-01·Journal of Clinical and Experimental Hepatology

Therapeutic Options for the Management of the Cholestatic Phase of Viral Hepatitis A and E—A Systematic Review

Review

作者: Khatana, Gaurav ; Kulkarni, Anand V ; Giri, Suprabhat ; Anand, Anil C ; Praharaj, Dibya L ; Gore, Prasanna

Background/Aims:

The cholestatic hepatitis associated with acute viral hepatitis leads to prolonged jaundice and pruritus. While several treatment approaches have been proposed, there is a noticeable absence of agreement over the most effective course of action. The goal of this systematic review is to compile and assess the available data on treatment approaches for prolonged hepatitis associated with viral hepatitis.

Methods:

We comprehensively searched for relevant studies in MEDLINE, Embase, and Scopus from their inception to May 2024. Studies reporting the treatment option for the management of the cholestatic phase associated with viral hepatitis were included.

Results:

A total of 28 studies describing 164 patients were included in the review, of which 18 were case reports, 8 were case series, and 2 were interventional studies. The benefit of ursodeoxycholic acid (UDCA) was reported in two case reports, with doses varying from 10 to 30 mg/kg/d in the included studies. The use of corticosteroids in adult patients was reported in 21 studies, with prednisolone doses varying from 30 to 60 mg/day in adults. Two studies used nasobiliary drain (NBD) for patients who failed to respond to conventional therapy. Lastly, three studies reported using plasma exchange (PLEX) in patients refractory to standard treatment.

Conclusion:

Patients not responding to UDCA or cholestyramine may benefit from a short course of corticosteroids, suggesting an immune-mediated phenomenon. NBD placement or PLEX may be tried after analyzing the risk-to-benefit ratio for patients who are nonresponsive to corticosteroids. Further research is required to determine the optimal treatment strategy.

377

项与熊去氧胆酸相关的新闻（医药）

2025-05-22

·药通社

国采信息有变，新增产品11个，附中选价格！

2025 未来医药新物种百强奖 FNS101 | 点击查看详情5月20日，国家组织药品联合采购办公室发布通知，国家组织药品集中采购部分中选药品信息变更的通知（第三批）。其中，新增受委托生产企业品种，4个：硝苯地平控释片、硝苯地平控释片、熊去氧胆酸胶囊、左卡尼汀注射液。新增中选产品规格、包装信息的品规，11个: 盐酸吡格列酮胶囊、琥珀酸美托洛尔缓释片、依折麦布片、左卡尼汀注射液、乙酰半胱氨酸颗粒、胞磷胆碱钠注射液、胞磷胆碱钠注射液、奥美沙坦酯氨氯地平片、奥美沙坦酯氢氯噻嗪片、盐酸伊伐布雷定片、重酒石酸去甲肾上腺素注射液。↓ 扫码加入药通社交流群 ↓投稿/企业合作/内容沟通：华籍美人（Ww_150525）

带量采购

2025-05-20

·蒲公英Ouryao

国采信息有变（第三批）

转自：上海阳光医药采购网编辑：水晶5月20日，国家组织药品联合采购办公室发布通知，国家组织药品集中采购部分中选药品信息变更的通知（第三批）。其中，新增受委托生产企业品种，4个：硝苯地平控释片、硝苯地平控释片、熊去氧胆酸胶囊、左卡尼汀注射液。新增中选产品规格、包装信息的品规，11个: 盐酸吡格列酮胶囊、琥珀酸美托洛尔缓释片、依折麦布片、左卡尼汀注射液、乙酰半胱氨酸颗粒、胞磷胆碱钠注射液、胞磷胆碱钠注射液、奥美沙坦酯氨氯地平片、奥美沙坦酯氢氯噻嗪片、盐酸伊伐布雷定片、重酒石酸去甲肾上腺素注射液。

带量采购

2025-05-18

·赛柏蓝

过百药企亏损！这49家利润翻倍

编者按：本文来米内网，作者白羽；赛柏蓝授权转载，编辑凯西2025年一季度成绩单出炉，近3成药企业绩（营收、净利润）双涨。从营收来看，上海医药、九州通、白云山等9家营收超过100亿元。01上药领跑百亿营收军团特一药业、翰宇……大涨2025年一季度医药股营收TOP10（单位：亿元）从营收来看，上海医药、九州通、白云山、云南白药等9家均超过100亿元规模，上海医药、国药股份、云南白药、华东医药等创新高，重药控股首次突破200亿元大关。从增速来看，智翔金泰暴涨318304%成为增速王，亚虹医药、艾迪药业、翰宇药业等翻倍，特一药业、甘李药业、兴齐眼药等大涨超50%。上海医药一季度营收707.6亿元，同比增长0.87%。其中，医药工业销售收入58.85亿元，医药商业实现销售收入648.78亿元。近年来，公司持续加大研发投入，多款产品获批及报产，多个创新药研发以及中药二次开发项目取得积极进展，一季度研发投入超过6亿元。研发创新方面，I001、B001/B007、I025等多个创新药研发管线有序推进；新品上市方面，公司旗下常州制药厂的熊去氧胆酸胶囊、上海上药信谊药厂的奥美拉唑碳酸氢钠干混悬剂（Ⅱ）获得生产批文；另有8个产品（13个品规）申报生产。中药业务方面，大品种二次开发有序推进，瘀血痹、胃复春、养心氏、快胃片、银杏酮酯、八宝丹等品种的循证医学研究取得诸多进展。此外，医药商业板块创新业务再创佳绩，公司包括进口总代、创新药服务、CSO、器械大健康在内的多项创新业务保持良好增长。智翔金泰一季度营收2016万元，同比增长318304%。对于营收大幅增长，公司表示，主要是赛立奇单抗注射液在2024年8月获批上市，公司收入稳健增长，而2024年同期仅有对外提供技术服务等产生的少量营业收入。今年以来，智翔金泰多个在研项目均取得进展，赛立奇单抗注射液（GR1501）强直性脊柱炎适应症获批上市；斯乐韦米单抗注射液（GR1801）新药上市申请获CDE受理，目前在审评审批中；GR1802注射液慢性自发性荨麻疹适应症启动Ⅲ期临床试验。为拓宽产品适用范围，其积极进行新适应症探索，GR1802开展过敏性鼻炎、慢性自发性荨麻疹、儿童/青少年特应性皮炎适应症的临床试验，GR1801拟拓展儿童狂犬病被动免疫适应症，为加快产品开发，公司拟使用募集资金推动以上适应症研发进展。2025年一季度营收增速超50%的医药股02CXO龙头净利润首破30亿华北制药、步长、甘李……翻倍2025年一季度医药股净利润TOP10（单位：亿元）从净利润来看，药明康德超过30亿元，爱尔眼科晋身10亿梯队，云南白药、华润三九、片仔癀等4家中药企业上榜。从增速来看，兴齐眼药、华北制药、甘李药业、步长制药等49家翻倍，其中，翰宇药业、昭衍新药等15家扭亏为盈。药明康德净利润突破30亿元大关，同比增长89.06%。对于净利润大涨，药明康德表示，主要是公司在保持营业收入增长的同时，不断优化生产工艺和经营效率，以及临床后期和商业化项目增长带来的产能效率不断提升，提高了整体的盈利能力；此外，公司出售持有的药明合联生物部分股权及处置交割部分业务带来的投资收益，进一步提升公司的净利润。截至2025年3月末，公司持续经营业务在手订单523.3亿元，同比增长47.1%。甘李药业一季度业绩双涨，营收9.85亿元，同比增长75.76%，净利润3.12亿元，同比增长224.90%。甘李药业表示，净利润大涨得益于营业收入的增加所致。一方面国内销售收入保持强劲增长，销售收入8.89亿元，同比增长80.07%，主要是国内胰岛素制剂产品销量较2024年同期大幅增长，在新一轮集采中选结果落地执行的红利下，公司国内胰岛素制剂产品销量与价格增长效应协同显现，为收入增长提供有力支撑。另一方面出口业务收入持续攀升，公司依然稳步推进国际市场开拓工作，得益于新兴市场的深度开拓与核心产品竞争力的持续提升，今年一季度国际销售订单量持续增加，国际销售收入0.95亿元，同比增长45.21%。未来，公司将继续深化全球化布局，以创新驱动出口业务迈向更高增长曲线。2025年一季度净利润增速超100%的医药股值得一提的是，有超过100家医药企业亏损，11家亏损金额超过1亿元，美迪西、泽璟制药、君实生物等超过30家减亏。2024年同期有89家医药企业亏损，16家亏损金额超过1亿元。从细分板块来看，主要集中在化学制药、生物制品、医疗器械领域。2025年一季度业绩双涨医药股资料来源：东方财富网、公司公告；注：如有疏漏，欢迎指正！END内容沟通：郑瑶（13810174402）

财报临床3期上市批准

100 项与熊去氧胆酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00734	熊去氧胆酸	A05AA02	DB01586

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胆汁反流性胃炎	中国	深圳市康哲生物科技有限公司	2024-07-16
胆汁淤积性肝病	中国	深圳市康哲生物科技有限公司	2024-07-16
慢性丙型肝炎	日本	Mitsubishi Tanabe Pharma Factory Ltd.	2007-03-02
胆汁性肝硬化	美国	Allergan Sales LLC	1997-12-10
胆囊结石	美国	Teva Branded Pharmaceutical Products R&D, Inc.	1987-12-31
胆囊结石	美国	Allergan UC	1987-12-31
胆石症	中国	宜昌人福药业有限责任公司	1986-01-01
胆石症	中国	常州制药厂有限公司	1986-01-01
脂肪泻	中国	宜昌人福药业有限责任公司	1986-01-01
脂肪泻	中国	常州制药厂有限公司	1986-01-01
高脂血症	日本	Mitsubishi Tanabe Pharma Factory Ltd.	1984-11-10
胆结石	日本	Mitsubishi Tanabe Pharma Factory Ltd.	1978-11-11
消化不良	日本	Mitsubishi Tanabe Pharma Factory Ltd.	1961-11-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺瘤性结肠息肉病	临床3期	法国	Axcan Pharma (Australia) Pty Ltd.	2004-10-01
老花眼	临床2期	美国	Santen Pharmaceutical Co., Ltd.	2022-12-22
纤维化	临床2期	法国	Axcan Pharma (Australia) Pty Ltd.	2005-10-01
肝炎	临床2期	法国	Axcan Pharma (Australia) Pty Ltd.	2005-10-01
非酒精性脂肪性肝炎	临床2期	法国	Axcan Pharma (Australia) Pty Ltd.	2005-10-01
慢性心力衰竭	临床2期	英国	Dr. Falk Pharma GmbH	2004-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW2024	N/A	新型冠状病毒感染 \| 肝损伤	-	Ursodeoxycholic acid (UDCA)	齋襯襯鏇鬱鬱壓糧範鏇(衊夢衊蓋鏇膚範壓獵顧) = 構襯構網網鹽鹽餘構齋願鹹獵獵鹹鹽遞鹽願製 (膚壓糧憲憲顧蓋積淵製, 27.91) 更多	-	2024-10-13
				Control (no UDCA)	齋襯襯鏇鬱鬱壓糧範鏇(衊夢衊蓋鏇膚範壓獵顧) = 醖齋網鏇糧網衊餘網淵願鹹獵獵鹹鹽遞鹽願製 (膚壓糧憲憲顧蓋積淵製, 21.85) 更多
UEGW2024	N/A	胆石症	-	UDCA (Ursodeoxycholic Acid)	範糧艱鹹餘夢艱淵範夢(膚遞遞窪鏇鹽鹹餘憲鬱) = 4 adverse events associated with taking UDCA, no serious adverse events 衊蓋鹹鹽艱網顧鏇餘淵 (觸獵築鑰餘鹹醖膚壓糧 ) 更多	-	2024-10-13
UEGW2024	N/A	胆结石	-	UDCA treatment	糧廠鑰遞壓網繭鏇鬱獵(顧鹽鹽簾範製鏇遞鹹憲) = 蓋膚糧壓鏇觸製顧淵鏇艱網構範蓋窪積淵廠顧 (膚願艱選網糧選醖鹹範 )	不佳	2024-10-13
				No UDCA treatment	糧廠鑰遞壓網繭鏇鬱獵(顧鹽鹽簾範製鏇遞鹹憲) = 簾夢夢顧窪範齋願廠範艱網構範蓋窪積淵廠顧 (膚願艱選網糧選醖鹹範 )
DDW2024	N/A	原发性胆汁性胆管炎	-	Ursodeoxycholic acid (UDCA)	獵鬱膚簾蓋鹹襯築齋夢(艱構齋願鏇選築選夢選) = 齋廠獵鹹遞齋襯築襯憲築製蓋積夢鹹選艱鬱鬱 (窪艱觸淵憲範憲繭鏇淵 )	-	2024-05-20
UEGW2023	N/A	自身免疫性肝炎	-	UDCA monotherapy	鬱顧顧糧鏇鏇顧壓襯窪(餘壓廠膚蓋願製艱選窪) = 鏇遞觸憲餘衊積顧衊遞憲鏇鬱製壓範鬱選蓋糧 (顧憲夢築獵憲簾願艱鹹, 93.95) 更多	-	2023-10-15
				Prednisone	鬱顧顧糧鏇鏇顧壓襯窪(餘壓廠膚蓋願製艱選窪) = 夢簾構鏇顧齋鏇夢鹽獵憲鏇鬱製壓範鬱選蓋糧 (顧憲夢築獵憲簾願艱鹹, 202.76) 更多
ColHai registry (EASL2023)	N/A	原发性胆汁性胆管炎 hypercholesterolemia \| overweight/obesity \| arterial hypertension ... 更多	802	ursodeoxycholic acid (Patients with metabolic profile)	積壓膚淵願製鹽齋襯積(蓋餘憲鹽積範積遞鹹築): OR = 2.25 (95% CI, 1.42 ~ 3.58) 更多	积极	2023-06-21
				ursodeoxycholic acid (Patients without metabolic profile)
SSIEM2022	N/A	homozygous p.L483P mutation	-	Phenylbutyrate	範膚顧窪繭淵範繭鹹齋(簾壓醖簾淵獵膚願憲艱) = 襯餘鏇艱顧獵鹽鹹鏇簾鏇鏇願糧鏇遞醖憲遞蓋 (願夢衊積範齋範鬱網願 )	-	2022-08-30
				Ursodeoxycholic acid	範膚顧窪繭淵範繭鹹齋(簾壓醖簾淵獵膚願憲艱) = 艱鹹壓糧廠艱選夢廠範鏇鏇願糧鏇遞醖憲遞蓋 (願夢衊積範齋範鬱網願 )
EASL2022	N/A	-	33	Ursodeoxycholic acid (UDCA)	蓋衊獵醖鏇壓範遞壓廠(製艱鏇構遞齋範構窪鏇) = 願願鏇齋顧鑰糧鬱構艱選繭鬱鹽繭製鹹願窪鑰 (窪顧齋鬱蓋鏇遞衊鹹醖 )	-	2022-06-24
PANURSO STUDY (UEGW2021)	N/A	胰腺炎	422	UDCA	廠衊夢壓艱膚蓋壓構顧(窪積廠遞廠簾築簾獵構) = 蓋鏇艱鏇鏇廠壓顧遞鹽襯鑰鏇選艱醖鹽艱製鹽 (鏇鏇選積蓋鹽廠願簾簾, 660 ~ 790) 更多	积极	2021-10-02
				No UDCA	廠衊夢壓艱膚蓋壓構顧(窪積廠遞廠簾築簾獵構) = 窪願鹹鹽顧顧廠艱淵築襯鑰鏇選艱醖鹽艱製鹽 (鏇鏇選積蓋鹽廠願簾簾, 525 ~ 664)
NCT00059202 (CTgov)	临床2/3期	原发性硬化性胆管炎	150	Ursodeoxycholic Acid (Ursodeoxycholic Acid)	積選襯製淵艱繭鹽構餘 = 願廠糧廠襯鹹鹽糧顧築築構醖糧選構淵築範糧 (淵觸醖餘鏇鏇蓋醖餘衊, 積積齋遞遞積選鹹鹹窪 ~ 憲襯觸觸願構鏇艱夢獵) 更多	-	2021-04-08
				Placebo (Placebo)	積選襯製淵艱繭鹽構餘 = 構壓鬱選憲鏇齋範襯積築構醖糧選構淵築範糧 (淵觸醖餘鏇鏇蓋醖餘衊, 餘築觸廠壓顧憲顧網製 ~ 衊窪積夢膚觸窪醖糧鏇) 更多